Choriocarcinoma, a rare but aggressive form of cancer, poses significant challenges in cancer research. Originating from abnormal placental tissue, it can occur after molar pregnancies or even during normal pregnancies. Despite its rarity, its rapid growth and propensity to metastasize demand urgent attention. Researchers focus on understanding its underlying genetic mutations and signaling pathways to develop targeted therapies. Additionally, advancements in imaging techniques aid in early detection and monitoring of the disease progression. Collaborative efforts among oncologists, geneticists, and reproductive specialists are crucial for improving treatment outcomes and fertility preservation options for affected individuals. Through interdisciplinary research endeavors, the quest to unravel the mysteries of choriocarcinoma continues, offering hope for more effective interventions and better prognoses in the future.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China